A Phase 2 interventional study of Sotagliflozin and Placebo in Nephropathy, Diabetic Nephropathies and Diabetes Mellitus, Type 1, sponsored by Steno Diabetes Center Copenhagen. Not yet recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-27.
Sponsored by Steno Diabetes Center Copenhagen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Diabetic Nephropathies with a site in Denmark — 6 open to participants now, 6 under way, none of them phase 3. Diabetic Nephropathies · Denmark.
Among the 42 studies in Diabetic Nephropathies with a site in Denmark, this one is the 17th largest by planned enrollment of the 36 interventional ones that give a count, is one of 2 that started in 2025, is one of 14 in phase 2, and was the 39th registered.
544 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.
Browse Diabetic Nephropathies studies →6 of the 42 studies in Diabetic Nephropathies with a site in Denmark are open now. Recruiting first, the newest first:
University of Aarhus · Sites in Denmark
Ages 40+
River 3 Renal Corp. · Sites in Denmark
Ages 18+
Herlev Hospital · Sites in Denmark
Ages 18–120
University Medical Center Groningen · Sites in Denmark, Finland
Ages 18–64
Mario Negri Institute for Pharmacological Research · Sites in Denmark, Italy, Spain
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 15 · Phase 3 5 · Phase 4 10
First in 1993; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 69 is below the median of 78 across 389 interventional studies indexed under Diabetic Nephropathies.
Median enrollment 61 across the 36 interventional studies, 144 across the 6 observational. Of the 31 that completed or were terminated, 8 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 42 have an industry lead sponsor. The 10 most frequent:
Steno Diabetes Center Copenhagen is the lead sponsor of 114 studies on the registry; 22 are open to participants now.
Steno Diabetes Center Copenhagen has 9 studies filed under Diabetic Nephropathies — fewer than ten, so there is no comparison to draw.
2 of the studies in Diabetic Nephropathies with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06600412River 3 Renal Corp.The Evaluation of the Drug R3R01 for the Excretion of Protein in the Urine in Patients With Diabetic Kidney Disease. | 2027-04-01 |
| NCT06147232Steno Diabetes Center CopenhagenPrevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxia | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 42 studies in Diabetic Nephropathies with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background: Sodium-glucose-cotransporter (SGLT) inhibition has been observed to reduce risk of cardiovascular events and kidney failure in persons with type 2 diabetes. People with type 1 diabetes also have increased risk of cardiovascular and kidney disease, and may benefit from SGLT-inhibition. The exact mechanism of how SGLT-inhibition benefits the kidneys are yet unknown. Change in renal hypoxia may be a factor.
Objective: The primary aim of this study is to assess the effects of 12 weeks SGLT-1 and 2 inhibition on renal oxygenation in persons with type 1 diabetes and chronic kidney disease.
Further aims are to study if renal oxygen consumption and response to SGLT-inhibition differs between people of African-Caribbean or Northern European decent.
Additionally effects on left ventricular ejection fraction, kidney function and biomarkers in blood and urine will be explored.
Method: 12 weeks treatment with oral sotagliflozin or matching placebo as intervention. Kidney oxygenation and perfusion parameters and left ventricular ejection fraction will be assessed by functional magnetic resonance imaging. Kidney function and biomarkers will be assessed according to local hospital laboratory guidelines.
Design: Randomized, double-blinded, placebo-controlled, cross over intervention study.
Study population: 69 persons with type 1 diabetes and diabetic kidney disease with albuminuria will be included, 39 at Steno Diabetes Center Copenhagen, 30 at King's College London.
Endpoints: Primary end-point: Change from 0 to 12 weeks in dynamic R2*-weighted signal after treatment with sotagliflozin compared to placebo. Secondary endpoints: Change from 0 to 12 weeks with sotagliflozin compared with placebo on renal perfusion, renal artery flow, renal oxygen consumption, renal parenchymal triglyceride fraction, renal fibrosis, left ventricular ejection fraction, urinary albumin-creatinin ratio, ketone bodies, erythropoietin, pro brain natriuretic peptide, and plasma- and urine inflammation- and fibrosis biomarkers as well as difference after 12 weeks treatment in glomerular filtration rate.
Timeframe: Inclusion of patients from february 2024. Last visit september 2025. Presentation spring 2026, publication fall 2026.
544 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.
This study's planned enrollment of 69 is below the median of 78 across 389 interventional studies indexed under Diabetic Nephropathies.
Browse Diabetic Nephropathies studies →Steno Diabetes Center Copenhagen is the lead sponsor of 114 studies on the registry; 22 are open to participants now.
Compared within Diabetic Nephropathies, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Kidney Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
first treatment period: 12 weeks placebo follow by: 6 weeks washout second treatment period: 12 weeks Sotagliflozin 200mg
Drug: Sotagliflozin · Drug: Placebo
first treatment period: 12 weeks Sotagliflozin 200mg follow by: 6 weeks washout second treatment period: 12 weeks placebo
Drug: Sotagliflozin · Drug: Placebo
Sodium-glucose-co-transporter 1 and 2 inhibitor
Also known as: Inpefa (TM)
Placebo tablet
Change in dynamic R2*-weighted signal (BOLD) as an indirect measure of renal blood oxygenation
difference between change from 0 to 12 weeks after treatment with sotagliflozin compared to treatment with placebo
Time frame: 0 to 12 weeks in both treatment arms, last measure 30 weeks after randomization.
Change in renal perfusion (medullary and cortical)
Measured with MRI by arterial spin labelling in mL/g/min
Time frame: From 0 to 12 weeks in each treatment arm. Last measure 30 weeks after randomization
Change in renal artery flow
Renal artery flow measured by using phase contrast (PC) MRI. It is measured in mL/min.
Time frame: From 0 to 12 weeks in each treatment arm. Last measure 30 weeks after randomization
Change in renal oxygen consumption
Renal oxygen consumption measured by MRI with T2-relaxation-under-spin-tagging.
Time frame: From 0 to 12 weeks in each treatment arm. Last measure 30 weeks after randomization
Change in renal parenchymal triglyceride fraction
Renal parenchymal triglyceride fraction is measured by MRI spectroscopy
Time frame: From 0 to 12 weeks in each treatment arm. Last measure 30 weeks after randomization
Change in renal fibrosis
Renal fibrosis is measured by MRI-derived apparent diffusion coefficient
Time frame: From 0 to 12 weeks in each treatment arm. Last measure 30 weeks after randomization
Change in left ventricular ejection fraction
Left ventricular ejection fraction is assessed by MRI
Time frame: From 0 to 12 weeks in each treatment arm. Last measure 30 weeks after randomization
Change in albuminuria
Urinary albumin-creatinine ratio (UACR) - morning void spot urine samples collected at home by participants.
Time frame: From 0 to 12 weeks in each treatment arm. Last measure 30 weeks after randomization.
Change in levels of ketone bodies
Capillary blood ketones, possibly measured by continous ketone monitoring device
Time frame: From 0 to 12 weeks in each treatment arm. Last measure 30 weeks after randomization.
Change in plasma and urine inflammation- and fibrosis biomarkers
Measured from blood and urine samples using a commercially available panel from the company Olink. Includes 92 biomarkers.
Time frame: From 0 to 12 weeks in each treatment arm. Last measure 30 weeks after randomization.
Change in endogenous erythropoietin
Analysis on blood samples at regional hospital laboratory.
Time frame: From 0 to 12 weeks in each treatment arm. Last measure 30 weeks after randomization.
Change in pro brain natriuretic peptide
Analysis on blood samples at regional hospital laboratory.
Time frame: From 0 to 12 weeks in each treatment arm. Last measure 30 weeks after randomization.
Difference in Kidney Function after 12 weeks treatment with sotagliflozin vs placebo
Glomerular filtration rate. At Steno Diabetes Center Copenhagen this will be measured by plasma clearance of Tc-99m diethylene-triamine-pentaacetate.
Time frame: From 12 to 30 weeks after randomization
Ethnicity
if African-Caribbean ethnicity is associated with any of the above secondary outcomes or baseline differences in cardio-renal disease markers/imaging measures
Time frame: From baseline to 30 weeks.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Feb 2025; primary completion for May 2027, 27 months later.
Of 52 phase 2 interventional studies under Diabetic Nephropathies, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's planned 27 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sotagliflozin
Steno Diabetes Center Copenhagen →